Locoregional breast cancer recurrence following targeted intraoperative radiotherapy (IORT) for ductal carcinoma in situ (DCIS)

Protocol: 
AAAQ7853
Phase: 
II

Locoregional breast cancer recurrence following targeted intraoperative radiotherapy (IORT) for ductal carcinoma in situ (DCIS)

The purpose of this study is to examine whether targeted Intraoperative
Radiotherapy (IORT) is as effective as external beam radiation in treating DCIS
and preventing it from returning. In addition, we will evaluate the side effects
of IORT (toxicity), imaging changes, cosmetic appearance of the breast and your
quality of life.
In this study, subjects with DCIS will have IORT during with breast conserving
surgery. Follow-up duration is 5 years.

Are you Eligible? (Inclusion Criteria)

To be eligible for this trial, patients must be:
- Female 18 years old or older with DCIS suitable for breast conserving
surgery and radiotherapy
- single tumor size less than or equal to 2 cm , no axillary lymph node
involvement and no metastases
-amenable to follow-up for at least 5 years.
- No prior treatment

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States